Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
about
Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s LymphomaChallenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicIn vivo targeting of B-cell lymphoma with glycan ligands of CD22.Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.A fifteen-year review of lymphomas in a Nigerian tertiary healthcare centre.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathyAIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral TherapyCancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Chemotherapy for gastro-enteropancreatic endocrine tumours.Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate.Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Modern management of non-Hodgkin lymphoma in HIV-infected patients.Human immunodeficiency virus - associated lymphomas: a neglected domain.Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.Immunotherapy for HIV-associated non-Hodgkin's lymphoma.Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.Nanomedicine strategies for hematological malignancies: what is next?Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphomaInfluence of water uptake, gel network, and disintegration time on prednisone release from encapsulated solid dispersions.R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
P2860
Q24240190-565D231F-9141-4735-B721-8887677D4769Q30244767-C80059DD-36D4-4DBA-84C2-42ED1F070BD8Q33911056-4D6B6D30-0511-47EB-A8D9-47EF5D3F322EQ33931886-A39DECFB-F1EE-47ED-B484-DB4EEC3BE8C1Q34470480-08C98B5A-266A-4493-8074-2D2118FD33C9Q35132483-149479F0-38E1-46C7-9F54-CFDAB733D6DEQ35305681-2DFD9A63-9054-4612-BF64-584F344588D4Q35673260-9D069F8A-81D4-488C-AAB1-B75E136C9AC8Q35779619-17F66737-0E7E-4D5E-AFBA-8782572C2CA5Q35786517-96275F42-559F-4FF0-AB2F-F9AE3F935F61Q35915027-0A11C3CB-5BC2-4498-B1A3-984AE815F30BQ35938319-D2306B84-1B31-4408-9A5D-6EC4C6E2C2B4Q36288013-888AE4D0-7DEA-4933-ABE1-5D7C32646751Q36334889-A34E6414-A15D-46DF-AF69-B45CCCE1B930Q36407441-B4BA49F5-D013-43E1-9F7D-EC150DF27E26Q36490052-A9ABD28F-A5D0-47CE-A069-21EBFFC99466Q36710347-9901F995-82DF-47DC-9225-617245FCC4CCQ37137151-012726C0-DC12-4C03-9643-1E5ADDC98FB7Q37411182-C2293779-8904-45B8-B3CA-7BDD67BEBD7BQ37567836-C913B1E7-3C44-4C5B-916C-C601D6FEB83DQ38140118-F752FAA2-4232-45B3-BE57-0E1318B99657Q38270098-07EC7033-9414-436B-A146-39979678B3CDQ40757934-A719CA78-0C56-4B78-80B7-3348C39543B7Q45923983-98A55AE1-CC30-4C1D-9FE1-F29A4CBFDA28Q46527308-C7320998-F4E7-439A-B976-66D5DA6B110EQ53165773-1534732D-55E7-4771-B5DA-A793FDD2DF39
P2860
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Liposome-encapsulated doxorubi ...... py and correlates of response.
@en
Liposome-encapsulated doxorubi ...... py and correlates of response.
@nl
type
label
Liposome-encapsulated doxorubi ...... py and correlates of response.
@en
Liposome-encapsulated doxorubi ...... py and correlates of response.
@nl
prefLabel
Liposome-encapsulated doxorubi ...... py and correlates of response.
@en
Liposome-encapsulated doxorubi ...... py and correlates of response.
@nl
P2093
P356
P1476
Liposome-encapsulated doxorubi ...... py and correlates of response.
@en
P2093
Alexandra M Levine
Andy Sherrod
Anil Tulpule
Bharat N Nathwani
Byron Espina
Lauri Welles
Robert D Lieberman
William D Boswell
P304
P356
10.1200/JCO.2004.10.093
P407
P577
2004-07-01T00:00:00Z